One in Seven Insulin-Treated Patients in Developing Countries Reported Poor Persistence With Insulin Therapy: Real World Evidence From the Cross-Sectional International Diabetes Management Practices Study (IDMPS)



PEER-REVIEWED INFOGRAPHIC

Juliana CN Chan, Juan José Gagliardino, Hasan Ilkova, Fernando Lavalle, Ambady Ramachandran, Jean Claude Mbanya, Marina Shestakova, Cecile Dessapt-Baradez, Jean-Marc Chantelot, Pablo Aschner



Background

For insulin-treated patients with diabetes, lack of persistence with insulin therapy may cause more severe hyperglycaemia than treatment with suboptimal adherence to dosage or frequency

Aim

Using data from Wave 7 of the IDMPS, we assessed persistence* with insulin therapy and reasons for poor persistence in patients with T1D or T2D in LMICs



IDMPS is an ongoing, non-interventional real-world study of clinical profiles and practices amongst patients receiving out-patient care in LMICs capturing 8 waves of data collection (2005–2020)

Wave 7 (2016–2017):

24 Countries 2000 Insulin-treated T1D 2596 Insulin-treated T2D **620** HCPs

RESULTS

- Non-persistence was reported by 14.0% of T1D and 13.7% of T2D patients
- Median total discontinuation of insulin therapy: 1–2 months
- Poor persistence in people with T1D and T2D was associated with:



age <40 years






low level of education



non-possession of a blood glucose meter

Main reasons for discontinuing insulin therapy:



*

Conclusions

Poor persistence with insulin is common amongst insulintreated patients with diabetes in developing countries, supporting calls for urgent action to ensure easy access to insulin, tools for SMBG and education.

Footnotes

*Persistence recorded as a 'yes'/'no' response to the following question: "Has the patient ever discontinued insulin therapy in the past?"

Abbreviations

HCP, healthcare professional; LMIC, low- to middle-income-country; IDMPS, International Diabetes Management Practices Study; SMBG, self-monitoring of blood glucose; T1D, type 1 diabetes; T2D, type 2 diabetes



This graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © The authors, CC-BY-NC 2021 DOI: 10.1007/s12325-021-01736-4